スライド 1

モバイル端末操作型エコー遠隔診断ロボット Smartphone Operated Tele-Echo Diagnosis Robot 4

非侵襲的内出血抽出アルゴリズム Non-invasively Internal Bleeding Extracting Algorithm 5

高感度DOI-PET検出器 High Sensitivity DOI-PET Detector 6

新しい乳がんのPET検査薬 Novel PET Reagent for Breast Cancer 7

人工赤血球の新しい臨床応用 New Clinical Applications of Artificial Red Cells 8

諸物性がデザインできる テーラーメイド輸送体によるDDS

DDS Based on Tailor-made Carriers Characterized by Designed Properties 9

コラーゲンを用いる新規DDS Novel DDS Using Collagen 10

生体内常在性物質による抗がん作用 Anti-cancer Effect by Resident Substance in vivo 11

海洋天然化合物 Marine Natural Products 12

機能性ペプチド合成法 Production Process of Functional Peptides 13

クエン酸濃度の迅速測定法 Quick Assay of Citric Acid 14

ワセダコレクション Waseda Collection 15

早稲田バイオサイエンスシンガポール研究所 Waseda Bioscience Research Institute in Singapore (WABIOS) 16

◆ 目 次 ◆

プレスリリース Press Release 2

非侵襲メラノーマ診断支援システム Non-invasive Melanoma Diagnosis SUPPORT SYSTEM 3

㙁憘㡴 岧 ℚ ⒉ ␇

Date Articles Sources

呹╤ቊ㦷ት↟㘰ሼቮ⺞⨚ዊኹአእᇷれᇸ 㡴⒙ぴ㯼㠿勭 㦬⒙

Small robots to cut down trees in automatic "tatumi" Nikkan Kogyo Shimbun, M.E.

拯椣㝜⇫ቊ㦷ት⒖ቭ⊡ሼዊኹአእᇷ⮸䵫ᇸ 㡴⒙ぴ㯼㠿勭 㦬⒙

Robot "Tenryu" that cuts down a tree with remote control Nikkan Kogyo Shimbun, M.E.

浧功㻃㊶䎰㳮⒕楱含 ▥ⷵぴ㯼㡴⫀ 㦬⒙

High water resistance inorganic separation membrane The Chemical Daily. M.E.

䜿⬒嵎㪊⚠ሴ䲊╤ዊኹአእ 㡴俛䞲㯼㠿勭 㦬⒙

Research environment for mobile robot Nikkan Kogyo Shimbun, M.E.

ኌኅዐ搇ቑ䉒ㄵት㟿䱡ቊ䂻⸩ሼቮ㔏嫢 㡴俛䞲㯼㠿勭 㦬⒙

Technique to measure citrate density in several seconds Nikkan Kogyo Shimbun, M.E. ኁዐኲወኅዐና㮫㪊㽤ᇬ㮫⒉㎮ㄵሯ᧭ₖ⊜ቑኘዐኒዙ 㡴㦻俛䂗㠿勭 ⮤⒙ Sensor, 10,000 times influenza detection sensitivity Nihon Keizai Shimbun, E.E. ䷕岧ቑ椪ᇬ┯燱䷘቎ቫቮ㦻㏚㊶㖾㒵ት㔠ራቮ孫┸⣷␆ 㡴俛䞲㯼㠿勭 㦬⒙ Assisting device that suppresses essential tremor by aging Nikkan Kogyo Shimbun, M.E.

嫏丰≽㈸቎㉫䞷ቊሰቮኧካ俕┄吞 㹝㡴㠿勭 㦬⒙

Nano plaster that can be applied to vessel repair Mainichi Shimbun, M.E.

⺞⨚㦷ሶቭዊኹአእ 㡴⒙ぴ㯼㠿勭 㦬⒙

Small woodcutter robot Nikkan Kogyo Shimbun, M.E.

ᇷ䞮✌初ⷵᇸቛቑ♥ቭ俓ቢ 崼⮁㠿勭 ⮤⒙

Action to "life aesthetics" Yomiuri Shimbun, E.E.

኉ዐኻ偩层䂻孔函ᇷ&$/(7ᇸ 㹝㡴㠿勭 㦬⒙

High-energy electrons, ɶ-ray observation equipment (CALET) Mainichi Shimbun, M.E.

⸖⸨ቑᇷ㤦煡䓸役ᇸቑ峋㕯 㡴㦻俛䂗㠿勭 ⮤⒙

Dark matter, the mystery of the universe 㻺㼕㼔㼛㼚㻌㻷㼑㼕㼦㼍㼕㻌㻿㼔㼕㼙㼎㼡㼚, E.E.

㷾䱠㌲劔ዊኹአእ 䞲俛㠿勭 㦬⒙

'HQWDOSDWLHQWURERW 㻿㼍㼚㼗㼑㼕㻌㻿㼔㼕㼙㼎㼡㼚㻘㻌㻹㻚㻱㻚㻌

ኝኁ዁完ኮዌዙ◙⺝⇢ 㡴㦻俛䂗㠿勭 㦬⒙

Diamond power semiconductor Nikkan Kogyo Shimbun, M.E.

⸖⸨ቊ㦏⒬ቑ㢮ᇰቑ⏘ቑ⚜㸚 㡴㦻俛䂗㠿勭 㦬⒙

Remnants of the light the stars of the first born Nikkan Kogyo Shimbun, M.E.

᧮㶰⏒ቑኲኀወኽ㢯⍞ቍቌቑ᧯'▥ 㡴⒙ぴ㯼㠿勭 㦬⒙

Effect of the 3D picture conversion from 2D picture film Nikkan Kogyo Shimbun, M.E.

㺦丰㗎丰㔏嫢ት峤∰቎ቊሰቮ岢傃䞷ዊኹአእ 㡴⒙ぴ㯼㠿勭 㦬⒙

Robot for tracheal intubation training Nikkan Kogyo Shimbun, M.E.

便卭ቑሯቶ▥㔠Ⓟ⥯⷟ቑ䔈⸩ 㡴⒙ぴ㯼㠿勭 㦬⒙

Identifying the factors necessary to repair cause of cancer _{Nikkan Kogyo Shimbun, M.E.}

ኧካ俕┄吞ᇷኧካኴ዆ኖኜዙᇸ 㡴㦻俛䂗㠿勭 㦬⒙

Nano-adhesive plaster _{Nikkan Kogyo Shimbun, M.E.}

便卭቎┪ት┯ራቮቋ便卭⒕孑ቑ抮ㄵሯ⮘ቲቮ 㡴俛䞲㯼㠿勭 㦬⒙

Controllable cell division, with the power Nikkan Kogyo Shimbun, M.E.

⇢␔㣑岗ቑ₼㨱 ኻኃኖ参␔ቊ层⹮ 㡴㦻俛䂗㠿勭 㦬⒙

Center of the body clock, observed in mouse brain in a living Nikkan Kogyo Shimbun, M.E.

便卭⒕孑ቑⓅ㈰ 㡴⒙ぴ㯼㠿勭 㦬⒙

Control cell division _{Nikkan Kogyo Shimbun, M.E.}

㠿侯㧟ᇷኾኚ⮩ⷣ⇢ᇸ 崼⮁㠿勭 ⮤⒙

New material 䇿MESOPOROUS䇿  Yomiuri Shimbun, E.E. 㻌                        P r e s s R e l e a s e

2

ࣖ ဇ ޒ

ޒ ᧏

᧏

᧏

 ǷȸǺϋܾ

ܾ

 Ꮡ

Ꮡ

Ꮡ  ୎

୎

୎

ᄂᆮƷȝǤȳȈƱΟˮࣱ

ࣱ

㻌㻌 㻌 ̛᩼᙭ႎ૾ඥỆợỦἳἻἠὊἰỉଔ஖ႆᙸᴾ

ᴾ ᴾ ᑥእЎ܇ἾἫἽỉऴإỆؕỀẪܲᚇႎẦếܭ᣽ႎễᚮૺૅੲᴾ

‡ Objective and quantitative diagnosis support based on the

information of the pigment molecules

ஊјႎễ඙ၲඥầசẻᄩᇌẰủềẟễẟᴾ

ἳἻἠὊἰỊᵏἱἼේ๾ẴỦắểỆʖࢸầಊỜềफẪễỦᴾ

ᢿЎႎễဃ౨Ịᛚᚮở᠃ᆆỉҾ׆ỆễỦئӳầẝỦᴾ

‡ Prognosis is very poor for each 1 mm invasion melanoma. ‡ Partial biopsy results in misdiagnosis and metastasis.

ἳἻἠὊἰử˂ỉᑥእࣱႝᐎ၌धẦỤᦷКẴỦἉἋἘἲửܱྵᴾ

ᑥእЎ܇ἾἫἽỉऴإỆؕỀẪܲᚇႎਦ೅ử੩̓ᴾ

ᐯᇌ׹ܦμᐯѣᚮૺૅੲἉἋἘἲᴾ

‡ System to disseminate from a melanoma from other pigmented

skin lesions

‡ Objective index based on the information of the pigment

molecules

‡ Complete automatic diagnosis support system

აࡁဇᡈហٳἡỶἣὊἋἬἁἚἽỶἳὊἊἵὊᴾ

ϋᙻᦟểኵỚӳỪẶềෞ֥҄၌धồᢘဇᴾ

ἡỶἣὊἋἬἁἚἻἽᶂᵿᶒᵿᶁᶓᶀᶃầ෇ဇỂẨỦЎ᣼ᴾ

‡ Near-infrared hyperspectral imager for ocular fundus diseases ‡ Digestive disorders in combination with an endoscope

‡ Field that can be leveraged the hyperspectral data cube

●研究者名： 宗田 孝之

●所属： 理工学術院 電気・情報生命工学科

Practical prototype MSI-03R

眼底用近赤外HSI

東京医科大学眼科における臨床研究を経て、 2013年度中に国立がん研究センター眼腫瘍科 における臨床研究を計画中

Nir-Hyperspectral imager for ocular fundus diseases

グリップに設置の 電磁ロック解除

スイッチ

ᴾ

̛᩼᙭ἳἻἠὊἰᚮૺૅੲἉἋἘἲᴾ

Non-invasive Melanoma Diagnosis SUPPORT SYSTEM

ࣖ ဇ ޒ

ޒ ᧏

᧏

᧏

 ǷȸǺϋܾ

ܾ

 Ꮡ

Ꮡ

Ꮡ  ୎

୎

୎

ᄂᆮƷȝǤȳȈƱΟˮࣱ

ࣱ

Point & Advantage

ʙ૏ྵئẦỤ၏ᨈộỂỉ૔࣯੿ᡛɶỆᵤᵟᵱᵲᚮૺὉ඙ၲửᘍảễẟᵆᵤᵟᵱᵲᵘᴾϋЈᘉỉ̛᩼᙭ႎᡆᡮᚮૺඥᵇᴾ ἿἮἕἚ২ᘐửဇẟỦẮểỂύྵئɧנỉҔࠖỆợỦᢒᨠᚮၲૅੲọẟềỊ૔ԡྙỉӼɥử׋ủễẟẦᾎᴾ ‡ Unable to make primary care (FAST) for trauma patients under conveyance to a hospital from accident scene ‡ Challenge to provide a robot tech. towards tele-FAST diagnosis by absent MD, then improving life-saving ratio

ᢒᨠעҔࠖỆợỦἴἢỶἽᇢ஛ỉદ˺Ểύ૔࣯੿ᡛɶỉٳͻधᎍỉϋЈᘉỉஊ໯ửᚮૺӧᏡᴾ ᧏ႆẲẺદ˺ỴἩἼὉἿἮἕἚὉᡫ̮২ᘐửکۡͤᚮỆ෇ဇẴỦẮểỂૼẺễἥἊ἟ἋἩἻὅửоЈᴾ ‡ Robot tele-operated with a smartphone to remotely search internal bleeding under conveyance ‡ Towards a new business : Tele-service of prenatal checkups based on RT, ICT and i-phone software

ỺἅὊỂϋЈᘉử̛᩼᙭ႎỆ੕ኧӧᏡễỸỹỴἻἨἽὉἿἮἕἚᵆधᎍ˳࠴ỉᾃᢿˮỆႺ੗ᘺბẴỦನᡯᵇử᧏ႆᴾ ἴἢỶἽᇢ஛ỂἩἿὊἨỉˮፗὉۋѬᛦૢửᘍảỦỴἩἼửဇẟỦẮểỂύᢒᨠẦỤỉႺᚇႎễἩἿὊἨદ˺ửܱྵᴾ ‡ Body-attachable robot technology enabling absent MD to

non-invasively search internal bleeding with ultra sonic

‡ i-phone software allowing to intuitively control position and

orientation of echo-probe with a smartphone or touch panel

‡ Medical services for patients requiring critical care in

long-travel ship & aircraft

‡ Prenatal checkups to reduce pregnant workload

(Cooperation with obstetricians on-going)

モバイル端末操作型エコー遠隔診断ロボット：FASTele

Tele-operated diagnosis robot: FASTele

FASTeleを用いた遠隔エコー診断システムのイメージ

Overview of tele-echo diagnosis system Using FASTele モバイル端末で直観的にプローブの位置や姿勢を操作可能 _{Location control application image}

ἴἢỶἽᇢ஛દ˺׹ỺἅὊᢒᨠᚮૺἿἮἕἚᴾ

Smartphone Operated Tele-Echo Diagnosis Robot

●研究者名： 岩田 浩康

●所属： 理工学術院 総合機械工学科



ࣖ ဇ ޒ

ޒ ᧏

᧏

᧏

 ǷȸǺϋܾ

ܾ

 Ꮡ

Ꮡ

Ꮡ  ୎

୎

୎

ᄂᆮƷȝǤȳȈƱΟˮࣱ

ࣱ

Point & Advantage

૔࣯ҔၲỆấẬỦϋЈᘉ౨Јίᾕᾐᾢᾣὸỉज़ࡇӼɥᴾ

ឬ᪦ඬဒ΂ϼྸỆؕỀẨᘉ෩ᝪသỉွ፯ሖ৑ửਁЈẴỦᚮૺૅੲἉἋἘἲỉನሰᴾ ‡ Improvement of FAST sensitivity in detecting internal bleeding in emergency medicine

‡ Constructing diagnostic system of extracting blood pool based on echo-image processing method

ᵤᵟᵱᵲỆợỦϋЈᘉ౨Јज़ࡇỊᵒᵑᵃỆသộẾềấụ

ᵊᴾϋЈᘉỉᙸᡜẲỉ˯ถầ࣯Ѧᴾ

ᘐࢸỉʖࢸởधᎍỉᾠᾞᾛỆ᧙̞ỉขẟЈᘉἅὅἚἿὊἽỉ᭗ࡇ҄ồỉ஖ࢳầ᭗ộụếếẝỦᴾ

ᾡᾣẦỤࢽỤủẺឬ᪦ඬପ΂ỉဒ΂ϼྸỆợụύϋЈᘉ᪸؏ ử੨Јᴾ ϋЈᘉầᝪသẲởẴẟᐥ֥᧓Ệ዁ụύឬ᪦ඬཎஊỉἠỶἌể ᘉ෩ỆợỦ˯᠗ࡇ᪸؏ểửғКẲếếύϋЈᘉᝪသửཎܭ ẴỦἉἋἘἲử᧏ႆᴾ ᴾ

‡ Extracting blood pool areas based on computer processing of

echo-images obtained by RT device

‡ Developing image-processing method to narrow down to the

low-intensity area near organ boundary while removing noises

ϋЈᘉᐯѣਁЈỴἽἆἼἌἲỉឬ᪦ඬᚮૺᘺፗồỉܱᘺᴾ ᵰᵲểỉᗡӳỆợỦᢒᨠᵤᵟᵱᵲᚮૺỆấẬỦϋЈᘉ౨ჷૅੲᴾ ‡ Adaption to regular ER operations by implementing to US devices ‡ Internal bleeding extracting assistance with RT in Tele-FAST

内出血貯留特定のシステムフロー

System flow of image processing to extract internal bleeding

FASTeleと本システムを用いたシステム全体像

Overview of ICT-RT integrated system for internal bleeding search

画像処理による臓器や内出血貯留領域の特定

Organs and internal bleeding area identified by image processing

本 全体像

̛᩼᙭ႎϋЈᘉਁЈỴἽἆἼἌἲᴾ

Non-invasively Internal Bleeding Extracting Algorithm

●研究者名： 岩田 浩康

ࣖ ဇ ޒ

ޒ ᧏

᧏

᧏

 ǷȸǺϋܾ

ܾ

 Ꮡ

Ꮡ

Ꮡ  ୎

୎

୎

ᄂᆮƷȝǤȳȈƱΟˮࣱ

ࣱ

᭗ज़ࡇᵢᵭᵧᵋᵮᵣᵲ౨Ј֥ᴾ

ဒ΂ᚮૺဇᵮᵣᵲᘺፗỉᚐ΂ࡇӼɥᴾ ỾὅἰዴỉԈӓˮፗẐᾂഏΨẑᚘยᴾ ᴾᴾ ᄬئ᎑ࣱỉૼẲẟҞݰ˳ήἍὅἇὊᴾ

‡ Resolution improvement for the PET scanner ‡ 3D measurement of incident gamma rays ‡ Novel optical sensor in the magnetic field

resistivity

ၶỉ၏ߺỉଔ஖ႆᙸᴾ

ἉὅἓἾὊἑϋᢿỉỾὅἰዴԈӓˮፗầɧദᄩᴾ ᙻ᣼ᇢỆấẟềӕࢽỶἳὊἊầٻẨẪപớᴾ ˯̖఍Ầếݱ׹ἍὅἇὊỉ࣏ᙲࣱᴾ

‡ Early detection of a carcinomatous lesion

‡ Inaccuracy of depth of interaction (DOI) of gamma rays within the scintillator ‡ Non-uniformity of PET image at the edge of vision

‡ Low-cost and compact PET detector is strongly awaited

ᵫᵮᵮᵡửဇẟẺૼẲẟᵢᵭᵧยܭඥửᄩᇌᴾ ᾂഏΨႎỆἇἨἱἼỉᚐ΂ࡇửܱྵᴾ

ᇤӳ২ᘐỆൔỔẆᙌ˺ầᢕẦỆܾତỂ᭗ࣱᏡᴾ ᵆᶃᵌᶅᵌᵊᴾᵶḚᶒᵿᶊᴾᵡᶓᶀᶃ౨Ј֥ᵇᴾ

‡ Novel simple DOI method using MPPCs

‡ Achieving sub-millimeter resolution in 3D

measurements of incident gamma-rays

‡ Very easy to fabricate, resolution better than

e.g., X tal Cube

᭗ज़ࡇᵮᵣᵲᴾᘺፗᴾ

ഏɭˊᵮᵣᵲᘺፗẆᵫᵰᵧᵍᵮᵣᵲᵊᴾᵲᵭᵤᵍᵮᵣᵲᴾ ݱ׹࿢ؾỾὅἰỽἳἻᴾ

‡ High Resolution PET scanner

‡ Next generation PET, MRI/PET, TOF/PET ‡ Small environmental gamma camera

PETの原理/DOI検出

Principles of PET/Detection of depth-of-interaction（DOI）

高精度三次元位置検出に向けたDOI測定法

DOI method for the precise 3D measurement of incident gamma-rays

High Sensitivity DOI-PET Detector

●研究者名： 片岡 淳

●所属： 理工学術院 応用物理学科



ࣖ ဇ ޒ

ޒ ᧏

᧏

᧏

 ǷȸǺϋܾ

ܾ

 Ꮡ

Ꮡ

Ꮡ  ୎

୎

୎

ᄂᆮƷȝǤȳȈƱΟˮࣱ

ࣱ

ૼẲẟʐầỮỉᵮᵣᵲ౨௹ᕤᴾ

Novel PET Reagent for Breast Cancer

ૼẲẟʐầỮỉᵮᵣᵲ౨௹ᕤᴾᾉᴾᵤᵣᵱᵕᵟᴾ

ᛦᙌ଺᧓ỉჺ጑ᴾᾉᴾᵤᵣᵱᵕᵟᾍᵤᵣᵱᴾ

ӓྙỴἕἩᴾᾉᴾᵤᵣᵱᵕᵟᴾᾍᴾᵤᵣᵱᴾ

ཎီࣱấợỎܭ᣽ࣱỉӼɥᴾᵘᴾᵤᵣᵱᵕᵟᾍᵤᵣᵱᴾ

ʐầỮᵮᵣᵲ౨௹Ịଔ஖ႆᙸᵍᚮૺỆấẟềஊဇᴾ

ᵹ

_{ᵤᵻ೅ᜤỺἋἚἿἄὅ᫏ጂ˳ίᵤᵣᵱὸỊܭ᣽ࣱởᛦᙌỆᛢ᫆ᴾ}

‡ Breast cancer PET is useful in diagnostic efficacy and diagnosis early

detection

‡ 18_{F-labeled estrogen analog (FES) is used for the breast cancer PET in the US}

‡ FES has the problem at the quantifiability and the preparation

※FES:16α-[18_{F]-fluoro-17β-estradiol}

マウスのPET撮像図 子宮、卵巣での集積が確認できる PET imaging in mice shows that tracer uptake in uterus and ovary

新規PET検査薬のマウス生体内分布測定 女性ホルモン受容体の存在が子宮・卵巣でそれぞれ示されている

Tissue distribution in mice

The graph shows the existence of estrogen receptors in uterus and ovary. It allows accurate diagnosis of breast cancer.

ᵱ

҄ӳཋἙἈỶὅểӳ঺২ᘐᴾ

ࣱ̮᫂ỉ᭗ẟᵣᵰἯἊἘỵἨễʐầỮ౨Јᴾ

‡ High reliable detection of ER positive breast tumors

‡ Novel PET reagent for breast cancer : FES7A ‡ Preparation time : FES7A, shorter than FES ‡ Yield : FES7A, higher than FES

‡ Specificity/Quantifiability：FES7A, higher than FES

ᴾᴾ ᴾ ᴾ ᴾ ᴾ ᴾ

ૼᙹễᵮᵣᵲỉʐầỮ౨௹ᕤᴾ

ỺἋἚἿἄὅ̔܍ࣱ၌धỉ౨௹ᴾ

‡ Novel PET reagent for breast cancer

‡ Examination for estrogen dependent disease

●研究者名： 岡本 真由美

ࣖ ဇ ޒ

ޒ ᧏

᧏

᧏

 ǷȸǺϋܾ

ܾ

 Ꮡ

Ꮡ

Ꮡ  ୎

୎

୎

ᄂᆮƷȝǤȳȈƱΟˮࣱ

ࣱ

ʴ߻ហᘉྶỉૼẲẟᐮ࠿ࣖဇᴾ

New Clinical Applications of Artificial Red Cells

ᘉሥࣱᖎᘉࣱ၌धỆấẬỦ˯ᣠእ᪸؏ồỉ ᣠእ̓ዅỆợỦయصߺỉ˯ถᴾ оͻ඙ၷјௐᵆႝࡰᡀᢒᢿˮỆᣠእ̓ዅὸᴾ ᕽဃИ஖ỆᵡᵭỂᖎᘉϐ໅්ͻܹử᧸ഥᴾ ᐥ֥ᆆౡẆϐ੗ბỉẺỜỉᐥ֥໅්෩ᴾ ྎҔ᪸؏ίἬἕἚờ᠞ᘉầ࣏ᙲᴾᴿᴿὸᴾ „ 血液型フリー „ 感染源フリー „ 室温保存２年可 „ 粒径250 nm „ 毒性なし     ‡ No blood type ‡ No pathogen ‡ Valid for 2 yrs. at r.t. ‡ Particle size 250nm ‡ No toxicity

‡ Oxygenation of ischemic tissues to minimize infarction. ‡ Wound healing by oxygenation of distal parts of a skin flap. ‡ Using CO at resuscitation to prevent reperfusion injury. ‡ Perfusate for organ transplantation or replantation.

‡ Veterinary medicine (Pets need transfusion, too !!).

250 nm

ク

クリーンルーム内での安定製造

Production in a clean room.

人工赤血球の投与により脳梗塞 領域が減少 (Neurosci Lett 2007);

Infarct size is minimized by artificial red cells (rat model).

人工赤血球 (ヘモグロビン小胞体)

Artificial Red Cell (Hemoglobin-vesicles)

ラット切断下肢を人工赤血球で灌流後、 再接着 ( 東 大 医 ・ 荒 木 淳 先 生 と の 共 同 研 究 );

Replantation of amputated leg after perfusion (Collaboration with Dr. Araki (Univ. of Tokyo).

Shear rate (s-1₎ 103 Flocculation Dissociation 100 101 102 103 104 105 Visc osity (cP) 106 10-4 ₁₀-3 ₁₀-2 ₁₀-1 ₁₀0 ₁₀1 ₁₀2 HES670 HES200 HES130 HES70 rHSA blood 8 28 PvO2 = 40 torr PaO2 = 110 torr 50 㻭㻙㼂㍑ᕪ㻌 0 SaO 2 (%) 0 20 40 60 80 100 50 100 150 PO2 (Torr) 左方シフトによる虚血領域への酸素 ターゲティング ;

Left shifted curve for O2 targeting to

ischemic tissue.

代用血漿剤の添加によるレオロ ジーコントロール ;

Rheology control by the combination with plasma expanders. ʴ߻ហᘉྶᵆᵦᶀݱᏘ˳ᵇᙌᡯỉؕႴ২ᘐᴾḤᵏᴾ ᧈ஖ܴภ̬܍ửӧᏡểẴỦᙌд҄২ᘐᴾḤᵐᴾ ɟᣠ҄໗እᵆᵡᵭᵇᢃ੿˳ểẲềỉМဇඥᴾḤᵑᴾ ᐥ֥̬܍෩ểẲềỉМဇඥᴾḤᵒᴾ ᵆḤᵏỊᵮᵡᵲЈᫍฎẆḤᵐᴾᵋᴾᵒỊཎᚩ঺ᇌฎỚᵇᴾ ᠞ᘉˊஆểẲềỉ৲ɨᚾ᬴ᚸ̖ඥᴾ

‡ Production method of artificial red cells (Hb-vesicles). ‡ Formulation for a long-term storage at room temperature. ‡ Carriers for carbon monoxide for cytoprotection.

‡ Perfusate for organ transplantation.

‡ Experiences for in vivo evaluation of safety and efficacy.

᠞ᘉဇᘉ෩ầᡈẟݩஹẆɧឱẴỦểỉʖยᴾ ྂᘉὉ᠞ᘉἉἋἘἲỉբ᫆ໜỉΰ஌ᴾ

ᣠእử࣏ᙲểẴỦ၌धỉ඙ၲẆٳᅹႎ඙ၲᴾ

‡ Shortage of blood supply in the near future ‡ Support for the blood donation-transfusion system ‡ Oxygen is required in therapies and surgeries

ʴ߻ហᘉྶᵆᵦᶀݱᏘ˳ᵇỉᙌᡯඥửᄩᇌᴾ

ܤμࣱὉஊјࣱỉᐔٻễἙὊἑử̬ஊᴾ ỽἩἍἽ҄ỆợụЎ܇ཞᵦᶀỉ൒ࣱửׅᢤᴾ

‡ Established production method of artificial red cells

‡ Abundant in vivo data of safety and efficacy studies

●研究者名： 酒井 宏水

●所属： 理工学術院 重点領域 (奈良医大)



ࣖ ဇ ޒ

ޒ ᧏

᧏

᧏

 ǷȸǺϋܾ

ܾ

 Ꮡ

Ꮡ

Ꮡ  ୎

୎

୎

ᄂᆮƷȝǤȳȈƱΟˮࣱ

ࣱ

‡ Controlled molecular assembling technology to efficiently and stably load drugs on carriers.

‡ DDS to specifically accumulate drugs in a target region by utilizing characteristic controlled nano-carriers (liposomes).

ᜂཋࣱầἙἈỶὅỂẨỦᴾ

ᴾ ḛἘὊἻὊἳỶἛ᠞ᡛ˳ỆợỦᵢᵢᵱḜᴾ

Drug Delivery Systems Based on Tailor-made Carriers Characterized by Designed Properties оᕤểᵢᶐᶓᶅᴾᵢᶃᶊᶇᶔᶃᶐᶗᴾᵱᶗᶑᶒᶃᶋᶑᵆᵢᵢᵱᵇửᗡӳẰẶỦἩἻἕἚἧỻὊἲᴾ Ἔἠ᠞ᡛ˳ỉཋࣱἙἈỶὅỆợụᕤཋѣ७ửСࣂᵆ཯ᐯỉೞᏡࣱᏢឋἻỶἨἻἼὊử̅ဇὸᴾ ૼᕤ᧏ႆỉьᡮẆ˄ь̖͌ᵢᵢᵱᙌдỉоЈᴾ

‡ Platforms to integrate drug discovery and drug delivery systems (DDS).

‡ Controlling pharmacokinetics of nano-carriers by designed properties with an original functional lipid library. ‡ Acceleration of new drug development, creation of value-added DDS pharmaceuticals.

ᕤд҄ӳཋỉ˳ϋѣ७ཎࣱửᙀܦẴỦૼᕤ᧏ႆỉἩἻἕἚἧỻὊἲᴾ

৴ầỮдẆἢỶỼҔᕤԼỉ೅ႎਦӼ׹ᵢᵢᵱᙌдẆἢỶỼỶἳὊἊὅἂдίᚮૺᕤὸᴾ

ഏɭˊ׹ᶒᶆᶃᶐᵿᶌᶍᶑᶒᶇᶁᙌдί඙ၲᕤểᚮૺᕤử᠞ᡛ˳Ệ઀᠍ὸᴾ

‡ New drug development platforms to improve the pharmacokinetics of drug compounds.

‡ Target-directing DDS for anti-cancer drugs and biomedicines. Bioimaging agents (diagnostic drugs).

‡ Future theranostic agents (Comprehensive platforms for therapeutic drugs and

diagnostic drugs).

分子集合制御技術により合成されるナノ輸送体によるDDS製剤 DDS formulations based on nano-carriers synthesized by controlled molecular assembling technology.

骨髄指向型ナノ輸送体（骨髄DDS製剤開発のプラット フォーム）の体内動態。投与量の約70%が骨髄に分布 Biodistribution of bone marrow-targeted nano-carriers (Platform for DDS targeting bone marrow). 70% of injected nano-carriers are distributed in bone marrow.

Inner aqueous phase

Water-soluble drugs

Lipid bilayer membrane

Lipo-soluble drugs

Rhesus monkey Rabbit

薬剤（候補）化合物

Drug (Candidate) Compounds

標的指向型DDS製剤 Target-directing DDS formulations 機能性脂質で修飾 Modification with functional lipids ᭗јྙỂܤܭỆᕤд҄ӳཋử᠞ᡛ˳Ệ઀᠍ẴỦẺỜỉЎ܇ᨼӳСࣂ২ᘐᴾᴾᴾᴾᴾ ཋࣱửСࣂẲẺἜἠ᠞ᡛ˳ίἼἯἏὊἲὸầᕤдử೅ႎᢿˮỆཎီႎỆᨼᆢ ẰẶỦᵢᵢᵱửܱྵᴾ ৲ɨẰủẺᕤдỊμ៲ỆЎࠋẴỦίμ៲ỉи˺ဇỆợỦधᎍỉᵯᵭᵪỉ˯ɦẆᕤཋ඙ၲỉᨂမὸᴾ ૼᕤͅᙀ҄ӳཋỉᵖᵎᵃầɧᢘЏễᕤཋѣ७ཎࣱỆợụἛἿἕἩỴỸἚᴾ Ӳᆔỉᕤд҄ӳཋửਃਤỂẨẆႸႎᢿˮỆᕤдửᡛᢋẴỦᵢᵢᵱਃ˳ỉ᧏ႆầ࣏ᙲᴾ

‡ Intravenously injected drugs are distributed in whole body (Decrease in

QOL of patients by side effects throughout the body, limitation of chemotherapy). ‡ 80% of the new drug candidate fail in development due to their

insufficient pharmacokinetics.

‡ Development of DDS materials which can load various drug compounds and specifically deliver them to target region is required.

●研究者名： 宗 慶太郎



ࣖ ဇ ޒ

ޒ ᧏

᧏

᧏

 ǷȸǺϋܾ

ܾ

 Ꮡ

Ꮡ

Ꮡ  ୎

୎

୎

ᄂᆮƷȝǤȳȈƱΟˮࣱ

ࣱ

ἋἘἽἋࣱể᭗ބ੎ඟࣱửਤếʻộỂỆ໯ẟᕤཋਃ˳ᴾ ৴Ҿࣱầ˯Ẫܤܭᴾ

‡ A new drug carrier with stealth in bloodstream

(no accumulation in organs) and high urinary excretion.

‡ Low immunogenicity and high stability.

ἅἻὊἄὅửဇẟỦૼᙹᵢᵢᵱᴾ

Novel DDS Using Collagen

‡ Polyethyleneglycol (PEG)-conjugation is not

always the best ; problems of biodegradation, tissue distribution, and antigenesity .

‡ Needs for alternatives to PEG.

‡ Peptidic drug carries: based on the collagen-like

triple-helical structure.

‡ Example: in vivo monitoring of oxidative stress.

ἢỶỼἰὊỽỆợỦܭ᣽ႎễބЎௌᴾ ᘉሥỉỶἳὊἊὅἂдᴾ

‡ Quantitative analysis of urine with biomarker ‡ Blood vessel imaging agent

コラーゲン様ペプチドの血中安定性

（ペプチド１∼３：コラーゲン様ペプチド、ペプチド７，８：ランダム コイルペプチド） Stability of collagen-like peptide in plasma.

尿中排泄されたコラーゲン様ペプチド-Proxylコンジュ ゲートによる酸化ストレスのモニタリング

Monitoring of oxdative stress using a Proxyl-peptide conjugate excreted in the urine

コラーゲン様３重らせんペプチドの特性 Property of collagen-like triple-helical peptides

ἅἻὊἄὅಮᾂ᣻ỤẶỮನᡯửཎࣉểẴỦẆἬἩἓἛࣱ ỉᕤཋਃ˳ẇᴾ ᘉɶᣠ҄ἋἚἾἋᚮૺᕤểẲềỉܱ଀̊ẝụẇᴾ ᕤཋਃ˳ểẲềɼ්ỉᵮᵣᵥ̲᫭ỊẆỼὊἽἰỶἘỵὊỂ ỊễẟẇဃЎᚐࣱẆᐥ֥ᆆᘍࣱẆ৴Ҿࣱỉբ᫆ᴾ ဃЎᚐẰủẵỆᵏᵎᵎήݣٳ੎ЈẰủỦợạễࣱឋửਤ ếᕤཋਃ˳Ị܍נẲễẟẇᴾ

●研究者名： 小出 隆規

●所属： 理工学術院 化学・生命化学科

10

ࣖ ဇ ޒ

ޒ ᧏

᧏

᧏

 ǷȸǺϋܾ

ܾ

 Ꮡ

Ꮡ

Ꮡ  ୎

୎

୎

ᄂᆮƷȝǤȳȈƱΟˮࣱ

ࣱ

ầỮኬᏘỆݣẲềᢠ৸ႎỆര๒Ὁف഻৮СẰẶỦ҄ӳཋᾧửႆᙸẲẺᴾ

҄ӳཋᾧỊဃ˳ϋỆࠝנẴỦཋឋỂẝỦẺỜи˺ဇầễẟᴾ

‡ Compound X that preferentially kills cancer cells and/or suppresses the its growth, was discovered. ‡ Since the compound X is existing in the human body, no side effects will be occurred.

化合物X存在・非存在下で培養したがん細胞数の変化 Change in the number of cancer cells cultured in the presence/absence of Compound X

正常細胞およびがん細胞に対する化合物Xの効果(５日間培養) The effects of compound X on normal or cancer cells (culture for 5 days)

Normal cells Cancer cells Control Compound X 0 50000 100000 150000 200000 250000 0 2 4 6 8 10

Cell number (cells/cm

2)

Days after seeding

Control

Compound X

ဃ˳ϋࠝנࣱཋឋỆợỦ৴ầỮ˺ဇᴾ

Anti-cancer Effect by Resident Substance

in vivo

ଏ܍ỉ৴ầỮ඙ၲඥỆỊẸủẹủჺ৑ầ܍נẲẆ඙ၲ଺ỆầỮधᎍỉᵯᵭᵪử˯ɦẰẶềẟỦᴾ धᎍỉᵯᵭᵪử˯ɦẰẶễẟ඙ၲඥỉ᧏ႆầஓộủềẟỦᴾ

̊ảị৴ầỮдỆỊи˺ဇầẝụẆधᎍỊầỮᐯ˳ỉᒊẲỚỉ˂Ệи˺ဇỉᒊẲỚỆờ᎑ảễẬủịễỤễẟᴾ ‡ Many existing therapies for cancer have own demerits and that demerits degrade cancer patients' QOL.

For example, it is well known that each anticancer agent has side effects.

‡ Consequently, cancer patients have to endure both illnesses of cancer and side effects. ‡ A new therapy, which sustains patients QOL, has been expected.

҄ӳཋᾧẆộẺỊẸỉỴἜἿἂửầỮኬᏘỆ৲ɨẴỦ ểẆര๒ấợỎف഻৮СјௐầỚỤủỦᴾ

ദࠝኵጢἴἙἽỉኬᏘỆݣẲềỊẆ҄ӳཋᾧỊࢨ᪪ ửɨảễẟᴾ

‡ Compound X or its analogs cause death and/or

growth suppression of the cultured cancer cells.

‡ On the other hand, normal cells are not affected

by the compounds.

҄ӳཋᾧửဇẟẺૼᙹầỮ඙ၲὉʖ᧸૾ඥỉ᧏ႆᴾ ҄ӳཋᾧửဇẟẺૼᕤỉ᧏ႆᴾ

‡ Development of new cancer treatment/prevention method

using the compound X

‡ Development of the new agent with compound X

●研究者名： 菊田敏輝

_{, 並木秀男}

●所属： 理工学研究所

_{, 教育・総合科学学術院}



ࣖ ဇ ޒ

ޒ ᧏

᧏

᧏

 ǷȸǺϋܾ

ܾ

 Ꮡ

Ꮡ

Ꮡ  ୎

୎

୎

ᄂᆮƷȝǤȳȈƱΟˮࣱ

ࣱ

ෙබ໯ᏨౢѣཋỊ˯Ў܇҄ӳཋỉܰࡉᴾ

ỺἦἊỹ἟ἘỵἁἋᄂᆮỉ἖ὊἽᴾ

‡ Marine invertebrates is a treasury of small compounds ‡ Tools of epigenetic studies

σဃࣇဃཋỉဃӳ঺ỆợỦ˯Ў܇҄ӳཋᴾ

σဃࣇဃཋỊؔ᫱ầ׉ᩊᴾ

ᆔẉἋἁἼὊἝὅἂỂ᭗ẟἤἕἚྙỉਁЈཋᴾ

‡ Small compounds by biosynthesis of symbiotic microbes ‡ Uncultivable symbiotic microbes

‡ High hit rate in various screenings for the extracts library

ෙබဃཋἇὅἩἽᴾ ᵐᵎᵎᵎᆔ᫏ˌɥᴾ

ෙබټ໱҄ӳཋᴾ ᴾ ᵏᵎᵎᆔ᫏ˌɥᴾ

‡ Marine biological samples 2000 kinds or more ‡ Marine natural compounds 100 kinds or more

ҔᕤԼἼὊἛ҄ӳཋᾉᘉሥૼဃ᧹ܹдẆ৴ज़௨ၐдẆᣞእ᧹ܹдẆሁᴾ

࠴ኬᏘဇᄂᆮ἖ὊἽᾉЎ̟҄ᡶдẆЎ҄᧹ܹдẆசЎ҄ዜਤдẆሁᴾ

ἃἱỽἽỺἦἊỹἝἁἋᄂᆮ἖ὊἽᾉᵢᵬᵟἳἓἽ҄᧹ܹдẆӲᆔἤἋ

Ἒὅ̲᫭Ẇሁᴾ

‡ Drug-lead compounds: anti-angiogenesis, anti-infective disease ,

enzyme inhibitors, etc.

‡ Tool for stem cell biology: differentiation promoters, differentiation

inhibitors, etc.

‡ Tools for chemical epigenetics: modulators of DNA methylation and

various histone modifications, etc.

ෙබټ໱҄ӳཋᴾ

Marine Natural Products

抗リーシュマニア剤： クリスタキセニシンA Anti-leishmaniasis: CristaxenicinA

抗感染症剤： ジブロモアジェリフェリン 血管新生阻害剤： アズマミド A Anti-angiogenic agent: Azumamide A

抗がん剤： シナントレン A Anti-cancer agent: Shinanthrene A

Anti-infective disease agent: dibromoageliferin

HO OH NH N H N HN N H NH N H N Br Br O H2N Br O NH2 Br O CHO OAc 18 OAc O H H HN H N HN O O O O NH2 O H N

●研究者名： 中尾 洋一

●所属： 理工学術院 化学・生命化学科

12

Substrate 1 Substrate 2 _{(by LC-ESI-MS analysis)} Products L-Pro L-Trp-L-Pro D-Pro L-Trp-D-Pro cis-4-L-Hyp L-Trp-cis-4-L-Hyp cis-4-D-Hyp L-Trp-cis-4-D-Hyp L-ProNH 2 L-Trp-L-ProNH 2 AZC L-Trp-AZC L-Pro-L-Pro L-Trp- L-Pro-L-Pro Methylamine L-Trp-Methylamine Dimethylamine L-Trp-Dimethylamine Azetidine L-Trp-Azetidine Pyrrolidine L-Trp-Pyrrolidine Piperidine L-Trp-Piperidine Azepane L-Trp-Azepane Azocane L-Trp-Azocane ȕ-Ala L-Trp-ȕ-Ala

Ȗ-Amino butylic acid L-Trp-Ȗ-Amino butylic acid L-Trp

ࣖ ဇ ޒ

ޒ ᧏

᧏

᧏

 ǷȸǺϋܾ

ܾ

 Ꮡ

Ꮡ

Ꮡ  ୎

୎

୎

ᄂᆮƷȝǤȳȈƱΟˮࣱ

ࣱ

ೞᏡࣱἬἩἓἛỉӳ঺ඥᴾ

Production Process of Functional Peptides

図１ チロシジン合成酵素由来TycAを利用したジペプチド合成プロセス Fig. 1. Production process for dipeptide utilizing tyrocidine biosynthetic enzyme

表１．TycA moduleを用いたＬ-Trpと求核化合物との反応 Table 1. The reaction of L-Trp and nucleophile with TycA module from NRPS for Tyrocidine synthesis

求核化合物：プロリン誘導体、プロリン類似化合物、β-アミノ酸、 γ-アミノ酸、ジペプチド、低分子アミノ、環状アミン

D-Amino acid L-Proline D-Amioacyl-L-proline

+

AMP+PPi AMP ATP

L-Amino acid L-Proline L-Aminoacyl-L-proline

+

ATP AMP+PPi

᩼ἼἮἏὊἲ׹ἬἩἓἛӳ঺ᣞእᵆᵬᵰᵮᵱᵇဌஹỉἴ

ἊἷὊἽởἛἳỶὅửМဇẲẺἊἬἩἓἛӳ঺ᴾ

ཎܭỴἱἠᣠỆᨂܭẰủễẟἊἬἩἓἛӳ঺২ᘐᴾ

from Non-Ribosomal Peptide Synthetase

‡ Dipeptide synthesis is not limited to a specific amino acid

ἬἩἓἛҔᕤԼỉࠊئਘٻᴾ

ἬἩἓἛỉјྙႎẆᢠ৸ႎች݅ӳ঺ỉἝὊἌᴾ

ᣞእඥỂỉᵢᵋỴἱἠᣠở᩼ټ໱ỴἱἠᣠỉМဇᴾ

‡ Available to D-amino acids or non-natural amino acids

in enzyme-catalyzed

ᵲᶗᶁᴾᵟἴἊἷὊἽỆợỦἊἬἩἓἛӳ঺ᴾ

ᵲᶗᶁᴾᵟỉᵟᴾᶂᶍᶋᵿᶇᶌỉỚỆợỦἊἬἩἓἛӳ঺ᴾ

ᵟᴾᶂᶍᶋᵿᶇᶌٶಮ҄ỆợỦӳ঺ἊἬἩἓἛỉਘࢌᴾ

ᵶᵿᵿᵋᵪᵋᵮᶐᶍỉٻ᣽ӳ঺ίᾶᵍᵪᵇᴾ

˓ॖỉỴἱἛ҄ӳཋỉӳ঺ᴾ

‡ Dipeptide synthesis by Tyc A module

‡ Dipeptide synthesis by A domain of Tyc A module ‡ Expansion of dipeptide using various A domains ‡ Large amount synthesis (g/L) of Xaa-L-Pro ‡ Available to synthesize any amide compound

ἩἿἼὅửᾒ஛ᇢỆᣐẲẺೞᏡἬἩἓἛỉӳ঺ᴾ

ἅἻὊἄὅಮἬἩἓἛỉӳ঺ᴾ

‡ Synthesis of functional peptide having proline residue

in the C-terminus. ex, ACE inhibitor, etc.

‡ Synthesis of Collagen-like peptide

アンジオテンシン変換酵素 阻害剤 Angiotensin converting enzyme inhibitor(ACE inhibitor)

●研究者名：木野 邦器

ࣖ ဇ ޒ

ޒ ᧏

᧏

᧏

 ǷȸǺϋܾ

ܾ

 Ꮡ

Ꮡ

Ꮡ  ୎

୎

୎

ᄂᆮƷȝǤȳȈƱΟˮࣱ

ࣱ

ࢼஹඥίᵏᵓЎᆉὸểီễụẆૠᅺỂยܭӧᏡᴾ

ஊೞ๋ۥở᭗̖ễᣞእửဇẟẵẆ౨Јज़ࡇầ᭗ẟᴾ ‡ Only several seconds to measure. (cf. conventional

method needs about 15 minutes)

‡ Organic solvent and expensive enzyme for extraction are unnecessary and high-sensitivity.

᫢Լỉᣠԛ঺ЎỂẝỦἁỺὅᣠỉຜࡇยܭᴾ

ࢼஹඥỊ᭗ᡮ෩˳ἁἿἰἚἂἻἧểӲᆔỽἻἲỉኵӳẶẆ ᣞእሁửဇẟỦܭ᣽ඥᴾ

‡ Concentration measurement of citric acid which is responsible for sour taste.

‡ Assay using high-performance liquid chromatography columns (HPLC) and enzyme is conventional.

ἁỺὅᣠỉຜࡇỆ̔܍ẲẺᖩήἍὅἇὊẆἁỺὅᣠኽӳ ἑὅἣἁឋểᵥᵤᵮỉᗡӳᴾ ဃ˳ຜࡇỆұẲẺᢘ࢘ễज़ӖࣱửਤẼẆኬᏘỆݰλẲề ဃ˳ϋỂ᩼ᄊْႎỆἼỴἽἑỶἲỂቇ̝ễยܭầӧᏡᴾ ἁỺὅᣠቇତยܭỿἕἚỉ᧏ႆᴾ ᫢ԼὉҔᕤԼὉ҄ታԼὉඹд঺ЎễỄỉЎௌᴾ ‡ Easy assay kit for citric acid

‡ Analysis for food, medicine, cosmetics and detergent etc.

ἁỺὅᣠຜࡇỉᡆᡮยܭඥᴾ

Quick Assay for Citric Acid

e

クエン酸濃度の上昇とともに蛍光強度が上昇するCF98と、減少する CF99の二種類を取得

Citrate concentration dependency on fluorescence in CF98 and CF99.

‡ Fusion protein of CitA (citrate sensor kinase A) and GFP, resulting fluorescent concentration sensor of citric acid ‡ The sensor can provide non-invasively real-time

monitoring in vivo.

クエン酸認識の特異性の評価 Substrate specificity of the sensor (CF99)

CF99の蛍光強度とクエン酸濃度 Fluorescence of CF99 and citric acid concentration 詳細 (for detail) ⇒ Y. Honda and K. Kirimura, PLoS ONE, 8, e64597 (2013).

Without citrate

With citrate

●研究者名： 桐村 光太郎

●所属： 理工学術院 応用化学科

Waseda Collection

Category

Item

Activity

marine natural 9-demethylaaptamine anti-Leishmania

isoaaptamine anti-Leishmania aaptamine anti-Leishmania Discodermin A Cytotoxicity,anti-microbial Discodermin B,C Cytotoxicity,anti-microbial Discodermin D Cytotoxicity,anti-microbial Halenaquinone Dnmt1 Xestoquinone Rad51 Corticatic Acid A Dnmt1 Aragusteroketal C Cytotoxicity Cupalourenol Cyclolaurenol Laurinterol Avarone Cytotoxicity,anti-angiogenesis,anti-microbial

Avarol

synthetic compd Estradiol-517 (Green)

Fluorescent Labeled Compounds

Estradiol-636 (Red) Progesterone-517 (Green) Pregesteron-636 (Red) Testosterone-517 (Green) Testosterone-636 (Red)

ent -Estradiol (enantiomer)

Negative probe for E2

[ 13 _{C 6 ]-Estradiol}

_{Stable isotope labeled compound}

[ 13 _{C 5 ]-5-Aminolevulinic acid} [ 13 _{C 6 ]-Indomethacin}

The other related labeled compounds are available.

【研究概要/Overview】

‹ フィジカルバイオロジー：メゾスコピック領域での新しい事象の発見と、生物機能の操作と解明。従来は マクロに捉えられていた「仕事(力)」と「熱(温度)」をミクロ・ナノレベルで扱う技術を開発し、生物学的に 重要な事象を発見します。

‡ Physical Biology : To develop micro/nanoscopic level technology to investigate mechanical work (power)

and heat (temperature), which are conventionally studied at the macroscopic level, in order to discover

important biological phenomena.

‹ バイオイメージング：His-tagタンパク質(遺伝子組換え技術で調製)に対して高い親和性を有するアダプター分 子を独自のスクリーニング法により開発してきました。これを発展させ、機能性ナノ粒子や機能性蛍光プ ローブの表面にHis-tagアダプター分子を結合させた新規プローブ群を構築します。

‡ Bio Imaging : An original screening method has been used to develop an adaptor molecule with high

affinity for the His-tag protein (that was produced by gene-recombination technology). Within the designated

time period, we will construct novel probe groups, which conjugate the His-tag adaptor molecule to the surface of functionalized nanoparticles or functionalized fluorescence probes.

‹ ケミカルバイオロジー：生体の情報伝達過程を可視化するために、蛍光タンパク質を基本としたバイオ機 能性材料を新規に開発、改良、発展させます。 また、この機能性材料を、生物個体内に導入することで、 生きたまま生体内の機能動態を可視化しつつ、解析します。

‡ Chemical Biology : The main research object is to visualize intracellular events such as signal transductions, gene expressions, and protein localizations with high spatio-temporal resolution in live animals. To visualize the intracellular events in live animals, we will develop gene-encoded fluorescent indicators based on green fluorescent proteins from jellyfish or coral, and generate the transgenic animals which bear fluorescent indicators.

‹ ナノバイオテクノロジー：人工赤血球について、国内外の研究機関との共同により、有効性と安全性を実 証し、人工赤血球の新しい利用法を展開しています。

‡ Nano Biotechnology： We collaborate with domestic and overseas research institutes to test their safety and efficacy aiming to clarify new usages of artificial red cells.

ଔᆖဋ

ἢỶỼἇỶỺὅἋἉὅỾἯὊἽ

ᄂᆮ৑ᴾ

Waseda Bioscience Research Institute in Singapore(WABIOS)

早稲田大学のWABIOSは、バイオサイエンスとバイオメディカルサイエンス研究を精力的に行って います。世界各国の優秀な研究者との交流を深め、精力的に共同研究、また、企業との産学連携も 積極的に推進しています。

WABIOS of Waseda University goes bioscience and the biomedical science research energetically .We deepen the exchange with an excellent researcher in every country in the world and are promoting a joint research aggressively. Also open for business-academia collaboration..

Highly thermosensitive Ca2+ _dynamics

Heat detection on the single cellular level

●詳細 ：http://www.waseda.jp/WABIOS/jp/about/

● More Information : http://www.waseda.jp/WABIOS/jp/about/

早稲田大学 研究推進部

産学官研究推進センター（承認ＴＬＯ）